IL120943A - מערכת למתן תרופות דרך העור - Google Patents

מערכת למתן תרופות דרך העור

Info

Publication number
IL120943A
IL120943A IL12094397A IL12094397A IL120943A IL 120943 A IL120943 A IL 120943A IL 12094397 A IL12094397 A IL 12094397A IL 12094397 A IL12094397 A IL 12094397A IL 120943 A IL120943 A IL 120943A
Authority
IL
Israel
Prior art keywords
insulin
skin
transdermal delivery
delivery system
iodine
Prior art date
Application number
IL12094397A
Other languages
English (en)
Other versions
IL120943A0 (en
Inventor
Amnon Sintov
Uri Wormser
Original Assignee
Univ Ben Gurion
Uri Wormser
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ben Gurion, Uri Wormser filed Critical Univ Ben Gurion
Priority to IL12094397A priority Critical patent/IL120943A/he
Publication of IL120943A0 publication Critical patent/IL120943A0/xx
Priority to EP98917589A priority patent/EP0975357B1/en
Priority to JP50043099A priority patent/JP2002501524A/ja
Priority to DE69832055T priority patent/DE69832055T2/de
Priority to US09/424,525 priority patent/US6274166B1/en
Priority to PCT/IL1998/000205 priority patent/WO1998053847A1/en
Priority to AU70770/98A priority patent/AU7077098A/en
Priority to US09/928,131 priority patent/US6667052B2/en
Publication of IL120943A publication Critical patent/IL120943A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL12094397A 1997-05-29 1997-05-29 מערכת למתן תרופות דרך העור IL120943A (he)

Priority Applications (8)

Application Number Priority Date Filing Date Title
IL12094397A IL120943A (he) 1997-05-29 1997-05-29 מערכת למתן תרופות דרך העור
EP98917589A EP0975357B1 (en) 1997-05-29 1998-05-04 Transdermal delivery system
JP50043099A JP2002501524A (ja) 1997-05-29 1998-05-04 経皮送達系
DE69832055T DE69832055T2 (de) 1997-05-29 1998-05-04 Transdermales abgabesystem
US09/424,525 US6274166B1 (en) 1997-05-29 1998-05-04 Transdermal delivery system
PCT/IL1998/000205 WO1998053847A1 (en) 1997-05-29 1998-05-04 Transdermal delivery system
AU70770/98A AU7077098A (en) 1997-05-29 1998-05-04 Transdermal delivery system
US09/928,131 US6667052B2 (en) 1997-05-29 2001-08-10 Transdermal delivery system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL12094397A IL120943A (he) 1997-05-29 1997-05-29 מערכת למתן תרופות דרך העור

Publications (2)

Publication Number Publication Date
IL120943A0 IL120943A0 (en) 1997-09-30
IL120943A true IL120943A (he) 2004-03-28

Family

ID=11070190

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12094397A IL120943A (he) 1997-05-29 1997-05-29 מערכת למתן תרופות דרך העור

Country Status (7)

Country Link
US (1) US6274166B1 (he)
EP (1) EP0975357B1 (he)
JP (1) JP2002501524A (he)
AU (1) AU7077098A (he)
DE (1) DE69832055T2 (he)
IL (1) IL120943A (he)
WO (1) WO1998053847A1 (he)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667052B2 (en) * 1997-05-29 2003-12-23 Ben Gurion University Of The Negev Research And Development Authority Transdermal delivery system
US6183773B1 (en) * 1999-01-04 2001-02-06 The General Hospital Corporation Targeting of sebaceous follicles as a treatment of sebaceous gland disorders
WO2000043058A1 (en) * 1999-01-22 2000-07-27 Powderject Research Limited Method of enhancing needleless transdermal powdered drug delivery
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
EP2269645A3 (en) 2000-08-16 2011-01-12 The General Hospital Corporation doing business as Massachusetts General Hospital Topical aminolevulinic acid-photodynamic therapy for acne vulgaris
BRPI0214168B8 (pt) 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) * 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
ES2398393T3 (es) 2002-03-01 2013-03-15 Dyax Corp. Péptidos de unión a KDR y a VEGF/KDR y su uso en diagnóstico y terapia
EP1587944A4 (en) 2002-03-01 2007-03-21 Dyax Corp KDR AND VEGF / KDR BINDING PEPTIDES AND THEIR USE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
JP2006504406A (ja) 2002-06-28 2006-02-09 セントカー・インコーポレーテツド 哺乳動物のｃｈ１欠失ミメティボディ、組成物、方法および使用
US8133505B2 (en) * 2002-10-31 2012-03-13 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
US7383084B2 (en) * 2002-10-31 2008-06-03 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
IL152574A (he) * 2002-10-31 2009-09-22 Transpharma Medical Ltd מערכת להולכה דרך העור של פריטים יבשים או תרופות מיובשות
US7662404B2 (en) * 2002-10-31 2010-02-16 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides
DK2949658T3 (en) 2003-03-03 2018-10-01 Dyax Corp Peptides that specifically bind HGF receptor (cMet) and uses thereof
US8524272B2 (en) 2003-08-15 2013-09-03 Mylan Technologies, Inc. Transdermal patch incorporating active agent migration barrier layer
UA89481C2 (uk) 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
WO2005097175A2 (en) 2004-03-31 2005-10-20 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses
ES2568259T3 (es) * 2004-05-13 2016-04-28 Alza Corporation Aparato y método para la administración transdérmica de agentes de hormona paratiroidea
US7393662B2 (en) 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
JO3058B1 (ar) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
CN101252951B (zh) 2005-06-30 2011-12-21 森托科尔公司 抗il-23抗体、组合物、方法和用途
EP1971366B1 (en) 2005-12-29 2014-07-30 Janssen Biotech, Inc. Human anti-il-23 antibodies, compositions, methods and uses
TW200843794A (en) 2006-12-21 2008-11-16 Centocor Inc Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles
ES2454974T3 (es) 2007-06-27 2014-04-14 The General Hospital Corporation Aparato para la inhibición óptica de la terapia fotodinámica
US7883487B2 (en) * 2008-06-16 2011-02-08 Shantha Totada R Transdermal local anesthetic patch with injection port
US8278419B2 (en) 2008-10-31 2012-10-02 Centocor Ortho Biotech Inc. Fibronectin type III domain based scaffold compositions, methods and uses
WO2010093627A2 (en) 2009-02-12 2010-08-19 Centocor Ortho Biotech Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
EP2552407A1 (en) 2010-03-31 2013-02-06 Wockhardt Limited Composition comprising insulin and herbal oil for transdermal or transmucosal administration
NZ603581A (en) 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
US9334306B2 (en) 2011-07-09 2016-05-10 The Regents Of The University Of California Leukemia stem cell targeting ligands and methods of use
US10383835B2 (en) 2012-03-14 2019-08-20 The Regents Of The University Of California Treatment of inflammatory disorders in non-human mammals
EP2852397B1 (en) 2012-05-18 2022-02-16 Janssen Biotech, Inc. Huwentoxin-iv variants and methods of use
US10414808B2 (en) 2012-05-18 2019-09-17 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
US10167341B2 (en) 2013-03-15 2019-01-01 Memorial Sloan Kettering Cancer Center High affinity anti-GD2 antibodies
MX2016004282A (es) 2013-10-03 2016-10-12 Janssen Biotech Inc Variantes de protoxina-ii y metodos de uso.
AU2015279712B2 (en) 2014-06-26 2021-03-25 Yale University Compositions and methods to regulate renalase in the treatment of diseases and disorders
MA41642A (fr) 2015-03-03 2018-01-09 Janssen Biotech Inc Variants de protoxine ii et méthodes d'utilisation
WO2016161100A1 (en) 2015-04-02 2016-10-06 Janssen Biotech, Inc. Protoxin-ii variants and methods of use
EA201892190A1 (ru) 2016-03-29 2019-04-30 Янссен Байотек, Инк. Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы
EP3484927A1 (en) 2016-07-15 2019-05-22 Poseida Therapeutics, Inc. Chimeric antigen receptors (cars) specific for muc1 and methods for their use
KR20190052669A (ko) 2016-07-15 2019-05-16 포세이다 테라퓨틱스, 인크. 키메라 항원 수용체 및 사용 방법
JP2020500152A (ja) 2016-09-30 2020-01-09 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で乾癬を治療する安全かつ有効な方法
EP3541422A4 (en) 2016-11-16 2020-05-06 Janssen Biotech, Inc. METHOD FOR TREATING PSORIASIS WITH A SPECIFIC ANTI-IL-23 ANTIBODY
KR20190113858A (ko) 2017-01-30 2019-10-08 얀센 바이오테크 인코포레이티드 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
MX2019009377A (es) 2017-02-07 2019-12-11 Janssen Biotech Inc Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa.
CN111727256A (zh) 2017-09-08 2020-09-29 波赛达治疗公司 用于嵌合配体受体（clr）-介导的条件性基因表达的组合物和方法
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
BR112020012555A2 (pt) 2017-12-20 2020-11-24 Poseida Therapeutics, Inc. composições de vcar e métodos para uso
IL310216A (he) 2018-03-05 2024-03-01 Janssen Biotech Inc שיטות לטיפול במחלת קרוהן עם נוגדן ספציפי אנטי-il23
SG11202008659TA (en) 2018-03-07 2020-10-29 Poseida Therapeutics Inc Cartyrin compositions and methods for use
US20190345245A1 (en) 2018-05-11 2019-11-14 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
WO2020016838A2 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
LT3883606T (lt) 2018-09-24 2023-09-11 Janssen Biotech, Inc. Saugus ir veiksmingas opinio kolito gydymo būdas anti-il12/il23 antikūnu
WO2020104943A2 (en) 2018-11-20 2020-05-28 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il-23 specific antibody
EP3897722A4 (en) 2018-12-18 2022-09-14 Janssen Biotech, Inc. SAFE AND EFFECTIVE METHOD OF TREATING LUPUS WITH AN ANTI-IL12/IL23 ANTIBODY
JP2022513507A (ja) 2018-12-20 2022-02-08 ポセイダ セラピューティクス，インコーポレイティド ナノトランスポゾン組成物および使用方法
BR112021013903A2 (pt) 2019-01-15 2021-09-21 Janssen Biotech, Inc. Composições e métodos de anticorpos anti-tnf para o tratamento da artrite idiopática juvenil
CA3127748A1 (en) 2019-01-23 2020-07-30 Janssen Biotech, Inc. Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis
MA55284A (fr) 2019-03-14 2022-01-19 Janssen Biotech Inc Procédés de production de compositions d'anticorps anti-tnf
WO2020183270A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
KR20210142002A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물을 생성하기 위한 제조 방법
KR20210141990A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-il12/il23 항체 조성물을 생성하기 위한 제조 방법
WO2020188466A1 (en) 2019-03-18 2020-09-24 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
AU2020279987A1 (en) 2019-05-23 2021-11-18 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
AU2020289070A1 (en) 2019-06-03 2022-02-03 Janssen Biotech, Inc. Anti-TNF antibody compositions, and methods for the treatment of Psoriatic Arthritis
CA3142580A1 (en) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
CN114761424A (zh) 2019-09-05 2022-07-15 波赛达治疗公司 同种异体细胞组合物和使用方法
CN115135672A (zh) 2019-12-20 2022-09-30 波赛达治疗公司 抗muc1组合物和使用方法
RU2745998C1 (ru) * 2020-01-17 2021-04-05 Акционерное Общество "Производственная Фармацевтическая Компания Обновление" Биоадгезивная антибактериальная композиция, способ ее изготовления (варианты)
CA3169529A1 (en) 2020-03-04 2021-09-10 Jingjing Jiang Compositions and methods for the treatment of metabolic liver disorders
US20230121433A1 (en) 2020-03-11 2023-04-20 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
US20230190811A1 (en) 2020-04-14 2023-06-22 Poseida Therapeutics, Inc. Compositions and methods for use in the treatment of cancer
WO2021214588A1 (en) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Anti-tnf alpha agent for treating coronavirus infections
WO2021214587A1 (en) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Anti-tnf alpha agent for treating viral infections
US20210386698A1 (en) * 2020-06-16 2021-12-16 Sailendra Nath Nichenametla Compositions and Methods for Preventing or Treating Diseases or Disorders Associated with Protein Misfolding
WO2022182797A1 (en) 2021-02-23 2022-09-01 Poseida Therapeutics, Inc. Genetically modified induced pluripotent stem cells and methods of use thereof
WO2022187671A1 (en) 2021-03-04 2022-09-09 Poseida Therapeutics, Inc. Compositions and methods for the treatment of hemophilia
BR112023018400A2 (pt) 2021-03-12 2023-12-12 Janssen Biotech Inc Método para tratamento de pacientes de artrite psoriática com resposta inadequada à terapia de tnf com anticorpo específico anti-il23
EP4305061A1 (en) 2021-03-12 2024-01-17 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
CN117916260A (zh) 2021-07-09 2024-04-19 詹森生物科技公司 用于制备抗il12/il23抗体组合物的制造方法
WO2023281462A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
JP2024526315A (ja) 2021-07-09 2024-07-17 ヤンセン バイオテツク，インコーポレーテツド 抗ｔｎｆ抗体組成物を製造するための製造方法
WO2023041985A2 (en) 2021-09-15 2023-03-23 New York University In Abu Dhabicorporation Compositions that block activation of the sars-cov-2 replication and transcription complex (rtc) and methods of use thereof
KR20240095537A (ko) 2021-10-04 2024-06-25 포세이다 테라퓨틱스, 인크. 트랜스포존 조성물 및 이의 이용 방법
IL312401A (he) 2021-10-29 2024-06-01 Janssen Biotech Inc שיטות לטיפול במחלת קרוהן עם נוגדן ספציפי אנטי-il23
US20230151087A1 (en) 2021-11-15 2023-05-18 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
IL313021A (he) 2021-11-23 2024-07-01 Janssen Biotech Inc שיטה לטיפול בקוליטיס כיבית עם נוגדן ספציפי אנטי- il23
WO2023164573A1 (en) 2022-02-23 2023-08-31 Poseida Therapeutics, Inc. Genetically modified cells and methods of use thereof
WO2023187707A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of treating mild to moderate psoriasis with il-23 specific antibody
WO2023193010A1 (en) 2022-04-01 2023-10-05 The Regents Of The University Of California Methods of improving cancer immunotherapy
WO2023223265A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody
WO2024036273A1 (en) 2022-08-11 2024-02-15 Poseida Therapeutics, Inc. Chimeric cd8-alpha co-receptor compositions and methods of use
US20240199734A1 (en) 2022-11-22 2024-06-20 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
WO2024178069A1 (en) 2023-02-21 2024-08-29 Poseida Therapeutics, Inc. Compositions and methods for genome editing
WO2024178086A1 (en) 2023-02-21 2024-08-29 Poseida Therapeutics, Inc. Aav piggybac transposon polynucleotide compositions and methods of use therefor
WO2024178055A1 (en) 2023-02-21 2024-08-29 Poseida Therapeutics, Inc. Compositions and methods for genome editing

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229410A (en) * 1978-02-13 1980-10-21 Kosti Carl M Bacteriostatic deodorant water coloring toilet element
LU84485A1 (fr) * 1982-11-22 1984-06-13 Oreal Nouvelle composition anti-acneique a base de peroxyde de benzoyle et d'au moins un autre principe actif
WO1985005036A1 (en) * 1984-04-30 1985-11-21 The Trustees Of Columbia University In The City Of Topical treatment of diabetes with insulin and penetrant enhancer applied to the skin and covered by a patch
WO1990001023A1 (en) * 1988-07-19 1990-02-08 American Biogenetics Corporation Method for solubilizing keratinaceous materials using alkaline hydrogen peroxide solution
WO1990000899A1 (en) * 1988-07-22 1990-02-08 Ciro's Touch, Ltd. Compositions and methods for treating skin conditions and promoting wound healing
US5707641A (en) * 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides

Also Published As

Publication number Publication date
WO1998053847A1 (en) 1998-12-03
EP0975357B1 (en) 2005-10-26
DE69832055D1 (de) 2005-12-01
US6274166B1 (en) 2001-08-14
EP0975357A1 (en) 2000-02-02
DE69832055T2 (de) 2006-07-20
AU7077098A (en) 1998-12-30
IL120943A0 (en) 1997-09-30
JP2002501524A (ja) 2002-01-15

Similar Documents

Publication Publication Date Title
EP0975357B1 (en) Transdermal delivery system
EP1556134B1 (en) Transdermal delivery system for dried particulate medications
US20070287949A1 (en) Transdermal System for Sustained Delivery of Polypeptides
EP0727221A2 (en) Composition of ionizing solvent
EP0643981B1 (en) A matrix for iontophoreses
CA2502146A1 (en) Solution formulations of sirolimus and its analogs for cad treatment
WO2009089181A1 (en) Insulin formulations for insulin release as a function of tissue glucose levels
WO1994010987A1 (en) Combined analgesic delivery methods for pain management
US8133505B2 (en) Transdermal delivery system for dried particulate or lyophilized medications
JPH0543453A (ja) 創傷治癒促進用局所用徐放性製剤
WO1985005036A1 (en) Topical treatment of diabetes with insulin and penetrant enhancer applied to the skin and covered by a patch
Golomb et al. A new route of drug administration: intrauterine delivery of insulin and calcitonin
US6667052B2 (en) Transdermal delivery system
CA2313618C (en) Transmucosal formulations of levosimendan
US20050118241A1 (en) Platform for transdermal formulations (ptf)
JP2012532852A (ja) ２型糖尿病における食後高血糖の経頬粘膜治療の方法、および当該治療に用いられる医薬組成物
Chien et al. Potential developments in systemic delivery of insulin
EA002023B1 (ru) Фармацевтическая композиция местного применения для введения в живой организм, содержащая пептидное лекарственное средство
JPH10265405A (ja) インスリン含有の皮膚外用製剤
Starr Innovations in drug delivery.
Lin et al. Drug delivery: controlled release
JPS63238017A (ja) 塩酸カルテオロ−ルを含有する水性外用貼付剤
PT1265629E (pt) Utilizacao da hormona de crescimento em dose baixa
CA2159609A1 (en) Factor xiii for treatment of skin wounds

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees